Ireland
--:--IST
Latest
Clinical Trials in Spain / NCT07040748
Recruiting Not applicable

Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome

NCT07040748 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2025-03-01
Last updated
2025-06-27

Condition(s) studied

Metabolic Syndrome

Investigational drug(s) / intervention(s)

Immersive VR-Based Multimodal Intervention (Virtual-METS)

Immersive VR-Based Multimodal Intervention (Virtual-METS): This intervention consists of a 12-week, group-based program using immersive virtual reality technology (MK360) without head-mounted displays. Each 60-minute session combines mindfulness practices adapted from the Mindfulness-Based Stress Reduction (MBSR) program, cognitive training targeting attention, processing speed, memory, and executive function through realistic virtual environments (such as parks, markets, or home interiors), and chair-based physical exercises focused on balance, stretching, and muscle strengthening. The intervention is delivered in small groups of five participants, twice per week, for a total of 24 sessions, and is led by a trained neuropsychologist.

Study summary

This study aims to evaluate the effectiveness of a multimodal intervention using immersive virtual reality (Virtual-METS) to improve cognitive function in middle-aged adults with metabolic syndrome and subjective cognitive complaints. The intervention combines cognitive training and physical exercise in group sessions over 12 weeks.

Eligibility

Sex
ALL
Min age
45 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Demonstrated criteria for the MetS: central obesity (waist circumference ≥ 94 cm for men or ≥ 80 cm for women) and at least 2 of the criteria described as follow: Triglycerides ≥ 150 mg/dl or specific treatment of this lipid disorder; HDL-C \< 40 mg/dl (men) or \< 50 mg/dl (women) or specific treatment of this lipid disorder; Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or previously diagnosed hypertension treatment; Basal glycemia ≥ 100 mg/dl or type 2 diabetes previously diagnosed). * Age: between 45 and 70 years old. * Subjective cognitive complaints: Subjective Cognitive Decline Questionnaire (≥ 7). * Ability to fully understand and speak Spanish or Catalan. Exclusion Criteria: * Confirmed or suspicion of dementia (MMSE\<24). * Diagnosis of severe psychiatric, neurological, developmental disorders, systemic pathologies, hematological, hormonal, nutritional pathology, and/or neoplasm that are known to cause cognitive deficits. * Other severe comorbidities considered a probable bias for the study: a cardiac history of unstable angina, recent myocardial infarction within the last 3 months, congestive heart failure, significant heart valve dysfunction, or unstable hypertension; taking medications that could negatively affect cognitive function. * Physical, motor, or sensory alterations that impede the neuropsychological examination or the rehabilitation program.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Consorci Sanitari de Terrassa Terrassa Spain Recruiting

More Consorci Sanitari de Terrassa trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07040748 on ClinicalTrials.gov ↗ ← All trials in Spain